As we work at increasingly higher Technology Readiness Levels (TRL 7+), we welcome Bethan and Stephen – whose combined experience bridges biocatalysis, continuous flow, process scale-up and industrial innovation to reduce our time to tech transfer and pilot scale manufacturing, accelerating commercial partnership timelines from 6-12 months to as little as 3-6 months.  

At the core of HydRegen's mission to make chemical manufacturing safer and more sustainable lies a team of exceptional scientists dedicated to pushing the boundaries of biocatalysis. Among them is Yinqi, a biologist whose journey into the field has been driven by a passion for understanding and transforming the natural world. 

With HydRegen, I was immediately struck not only by the energy and ambition of the team, but also by the potential HydRegen technology has to make a real impact in the pharmaceutical sector and many others. Their innovative biocatalysis technology provides an efficient and sustainable alternative to traditional chemical manufacturing processes, and they have already started to demonstrate real world applications and impact.

HydRegen successfully completes tech transfer to Almac Sciences as part of the joint development project of its proprietary enzyme platform.

HydRegen and researchers from the University of Nottingham’s Faculty of Engineering collaborate in a project to unlock sustainable biocatalytic hydrogenation and receive grant funding from BBSRC, EPSRC and IUK to complete the feasibility study.